Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

277 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Killer immunoglobulin-like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment-free remission.
Dumas PY, Bérard E, Bréal C, Dulucq S, Réa D, Nicolini F, Forcade E, Dufossée M, Pasquet JM, Turcq B, Bidet A, Milpied N, Déchanet-Merville J, Lafarge X, Etienne G, Mahon FX; French Intergroup in Chronic Myeloid Leukemia. Dumas PY, et al. Among authors: berard e. Cancer Med. 2019 Sep;8(11):4976-4985. doi: 10.1002/cam4.2371. Epub 2019 Jul 9. Cancer Med. 2019. PMID: 31287239 Free PMC article.
Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia.
Dumas PY, Bertoli S, Bérard E, Médiavilla C, Yon E, Tavitian S, Leguay T, Huguet F, Forcade E, Milpied N, Sarry A, Sauvezie M, Bories P, Pigneux A, Récher C. Dumas PY, et al. Among authors: berard e. Oncotarget. 2017 Mar 7;8(45):79126-79136. doi: 10.18632/oncotarget.15988. eCollection 2017 Oct 3. Oncotarget. 2017. PMID: 29108292 Free PMC article.
Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study.
Dumas PY, Bertoli S, Bérard E, Largeaud L, Bidet A, Delabesse E, Leguay T, Leroy H, Gadaud N, Rieu JB, Vial JP, Vergez F, Lechevalier N, Luquet I, Klein E, Sarry A, de Grande AC, Pigneux A, Récher C. Dumas PY, et al. Among authors: berard e. Cancers (Basel). 2020 Jul 24;12(8):2044. doi: 10.3390/cancers12082044. Cancers (Basel). 2020. PMID: 32722211 Free PMC article.
Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes.
Galtier J, Alric C, Bérard E, Leguay T, Tavitian S, Bidet A, Delabesse E, Rieu JB, Vial JP, Vergez F, Lechevalier N, Luquet I, Klein E, de Grande AC, Sarry A, Pigneux A, Récher C, Bertoli S, Dumas PY. Galtier J, et al. Among authors: berard e. Blood Cancer J. 2021 Nov 13;11(11):180. doi: 10.1038/s41408-021-00551-y. Blood Cancer J. 2021. PMID: 34775463 Free PMC article. No abstract available.
Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry study.
Gadaud N, Leroy H, Bérard E, Tavitian S, Leguay T, Dimicoli-Salazar S, Rieu JB, Luquet I, Largeaud L, Bidet A, Delabesse E, Klein E, Sarry A, de Grande AC, Bories P, Pigneux A, Récher C, Dumas PY, Bertoli S. Gadaud N, et al. Among authors: berard e. Leuk Lymphoma. 2022 Jun;63(6):1398-1406. doi: 10.1080/10428194.2021.2022140. Epub 2022 Jan 4. Leuk Lymphoma. 2022. PMID: 35634787
A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries.
Bérard E, Röllig C, Bertoli S, Pigneux A, Tavitian S, Kramer M, Serve H, Bornhäuser M, Platzbecker U, Müller-Tidow C, Baldus CD, Martínez-Cuadrón D, Serrano J, Martínez-Sánchez P, Arbolí ER, Gil C, Bergua J, Bernal T, de la Fuente Burguera A, Delabesse E, Bidet A, Dumas PY, Montesinos P, Récher C. Bérard E, et al. Blood Cancer J. 2022 Jul 11;12(7):107. doi: 10.1038/s41408-022-00700-x. Blood Cancer J. 2022. PMID: 35821023 Free PMC article.
Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse-Bordeaux DATAML Registry Study.
Bertoli S, Dumas PY, Bérard E, Largeaud L, Bidet A, Delabesse E, Tavitian S, Gadaud N, Leguay T, Leroy H, Rieu JB, Vial JP, Vergez F, Lechevalier N, Luquet I, Klein E, Sarry A, Grande AC, Récher C, Pigneux A. Bertoli S, et al. Among authors: berard e. Cancers (Basel). 2020 Mar 25;12(4):773. doi: 10.3390/cancers12040773. Cancers (Basel). 2020. PMID: 32218221 Free PMC article.
Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome.
Dumas PY, Bertoli S, Bérard E, Leguay T, Tavitian S, Galtier J, Alric C, Bidet A, Delabesse E, Rieu JB, Vial JP, Vergez F, Lechevalier N, Luquet I, Klein E, Sarry A, Rey H, de Grande AC, Despas F, Pigneux A, Récher C. Dumas PY, et al. Among authors: berard e. Blood Adv. 2020 Aug 25;4(16):3840-3849. doi: 10.1182/bloodadvances.2020002511. Blood Adv. 2020. PMID: 32790847 Free PMC article.
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries.
Récher C, Röllig C, Bérard E, Bertoli S, Dumas PY, Tavitian S, Kramer M, Serve H, Bornhäuser M, Platzbecker U, Müller-Tidow C, Baldus CD, Martínez-Cuadrón D, Serrano J, Martínez-Sánchez P, Arbolí ER, Gil C, Bergua J, Bernal T, de la Fuente Burguera A, Delabesse E, Bidet A, Pigneux A, Montesinos P. Récher C, et al. Among authors: berard e. Leukemia. 2022 Apr;36(4):913-922. doi: 10.1038/s41375-021-01425-9. Epub 2021 Nov 13. Leukemia. 2022. PMID: 34775483 Free PMC article.
277 results